Elevance Health, Inc. (ELV) Stock Price & How to Invest

Elevance Health (formerly Anthem) is a diversified health insurer and healthcare services company that covers roughly 45.6 million medical members as of mid 2025. Its Health Benefits segment sells commercial, Medicare Advantage, Medicaid, and ACA marketplace plans, operating Blue Cross Blue Shield plans across 14 states, while its fast-growing Carelon segment houses pharmacy benefits (CarelonRx) and risk-based care services. Operating revenue reached roughly $197.6 billion in 2025, with Carelon revenue climbing about 33 percent on CarelonRx growth and the CareBridge acquisition.

The investment picture is that of a mature, defensive cash machine trading at a low earnings multiple, reflecting market worry about medical cost inflation rather than doubt about the franchise. Management raised full-year 2026 adjusted EPS guidance to at least roughly $26.75 after a Q1 2026 beat, but flagged a higher benefit expense ratio driven by Medicaid cost trend. Investors weigh Elevance's scale, diversification into services, and shareholder returns against a regulated, thin-margin insurance model where a few points of medical loss ratio move earnings materially.

The dominant risk is medical cost trend: the benefit expense ratio (medical loss ratio) ran near 86.8 percent in Q1 2026 and rising Medicaid and Medicare utilization can compress margins faster than premiums reprice. Elevance is heavily exposed to government programs, so Medicaid rate adequacy, Medicare Advantage rate notices, and ACA subsidy policy are all regulatory swing factors outside its control. Integration risk from acquisitions like CareBridge, litigation and audit exposure common to large payers, and the political sensitivity of health insurer profits add further uncertainty. Because insurance margins are thin, a few points of adverse medical loss ratio can move earnings sharply, which is a key reason the stock carries a low multiple.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Elevance Health, Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$200 billion
• FY2025 operating revenue: ~$197.6 billion
• FY2025 net income: ~$5.7 billion
• FY2026 adjusted EPS guidance: at least ~$26.75
• Market cap: ~$83 billion
• Trailing P/E: ~11.5x
• Medical membership: ~45.6 million

Elevance trades at a low double-digit earnings multiple, reflecting investor caution on medical cost trend rather than doubt about scale. Q1 2026 operating revenue was roughly $49.5 billion with adjusted EPS of about $12.58, and management raised full-year guidance while reaffirming its benefit expense ratio target near 90.2 percent. These figures are approximate and as of April 2026; verify current numbers before acting.

There are three common ways to get ELV exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so ELV sits alongside other stocks that express the same thesis.

Walnut takes the basket route. Describe a thesis where ELV fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

Elevance is a scaled, low-multiple health insurer whose story hinges on managing medical cost trend across its Health Benefits and Carelon segments rather than on rapid growth.

Whether ELV is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is ELV a buy?, and where the stock could go from here in the ELV stock forecast.

For income investors, whether ELV pays a dividend and how the payout looks is covered in does ELV pay a dividend?